Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)

ABSTRACT: Background: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. Methods: Open-label, single-arm, 48-week pilot trial. HIV-...

Full description

Bibliographic Details
Main Authors: Rosa De Miguel, David Rial-Crestelo, Lourdes Dominguez-Dominguez, Rocío Montejano, Andrés Esteban-Cantos, Paula Aranguren-Rivas, Natalia Stella-Ascariz, Otilia Bisbal, Laura Bermejo-Plaza, Mónica Garcia-Alvarez, Belén Alejos, Asunción Hernando, Mireia Santacreu-Guerrero, Julen Cadiñanos, Mario Mayoral, Juan Miguel Castro, Victoria Moreno, Luz Martin-Carbonero, Rafael Delgado, Rafael Rubio, Federico Pulido, José Ramón Arribas
Format: Article
Language:English
Published: Elsevier 2020-05-01
Series:EBioMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420301547

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420301547

Similar Items